Brooklyn Investment Group Purchases 36 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brooklyn Investment Group raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 520 shares of the biopharmaceutical company’s stock after buying an additional 36 shares during the quarter. Brooklyn Investment Group’s holdings in Regeneron Pharmaceuticals were worth $547,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in REGN. Quantbot Technologies LP acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $151,000. D.A. Davidson & CO. lifted its stake in Regeneron Pharmaceuticals by 5.1% during the third quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock worth $863,000 after purchasing an additional 40 shares during the period. Bank of Montreal Can boosted its holdings in Regeneron Pharmaceuticals by 1.5% during the third quarter. Bank of Montreal Can now owns 188,157 shares of the biopharmaceutical company’s stock valued at $196,189,000 after purchasing an additional 2,866 shares in the last quarter. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Independent Advisor Alliance acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $231,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Oppenheimer dropped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:REGN opened at $749.51 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market cap of $82.36 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 2.84 and a beta of 0.15. The company has a 50 day moving average of $937.00 and a 200-day moving average of $1,025.99. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.